Mehmet POLATLI, Nurhayat YILDIRIM, TUNÇALP DEMİR, Hakan GÜNEN

KOAH’da inhaler kortikosteroid/uzun etkili beta-2 agonist fiks kombinasyonunun etkileri

Kronik obstrüktif akciğer hastalığı (KOAH) progresif hava akımı kısıtlanması ile karakterize ve 2030 yıllarında dünyada üçüncü ölüm nedeni olacağı tahmin edilen inflamatuvar bir hastalıktır. Son 10 yılda yapılan çalışmalar fiks kombinasyonun (inhaler kortikosteroid/uzun etkili beta-2 agonist; İKS/LABA) ağır ve çok ağır KOAH olgularında akciğer fonksiyonlarını ve yaşam kalitesini iyileştirdiğini, semptomları ve atak sıklığını azalttığını göstermiştir.

Effects of inhaled corticosteroids/long-acting beta-2 agonist fix combinations in COPD

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized with progressive air flow limitation, and is expected to be the third leading cause of death until 2030 worldwide. The clinical trials in the last 10 years revealed that fix combinations (inhaled corticosteroids/long-acting beta-2 agonist; ICS/LABA) improve lung functions and quality of life, and reduced symptoms and exacerbation rates in patients with severe and very severe COPD.

PDF

___

1. Rennard SI, Barnes PJ. Pathogenesis of COPD. In: Barnes PJ, Drazen JM, Rennard S, Thomson NC (eds). Asthma and COPD. London: Academic Press, 2002: 361-79.
2. Chung KF. Cytokines in COPD. Eur Respir J 2001; 34 (Suppl): 50-9.
3. Patel IS, Roberts NJ, Lloyd-Owen SJ, et al. Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J 2003; 22: 94-9.
4. Balzano G, Stefanelli F, Iorio C, et al. Eosinophilic inflammation in stable COPD: relationship with neutrophils and airway function. Am J Respir Crit Care Med 1999; 160: 1486-92.
5. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 557-72.
6. Hall IP. β-2 adrenoceptor agonists. In: Barnes PJ, Drazen JM, Rennard S, Thomson NC (eds). Asthma and COPD. London: Academic Press, 2002: 521-6.
7. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11: 86-90.
8. Hui KP, Ventresca P, Brown AC, et al. Modulation of neurally mediated airway microvascular leak in guinea pig airways by beta-2 adrenoceptor agonists. Agents Actions 1992; 32: 29-33.
9. Hansel TT, Barnes PJ. Drug therapy for stable COPD. In: Hansel TT, Barnes PJ (eds). An Atlas of COPD. London: The Parthenon Publishing Group, 2004: 135-200.
10. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172: 704-12.
11. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available from www.goldcopd.org Updated 2009.
12. www.nice.org.uk/CG101
13. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of COPD. Eur Respir J 2003; 21: 74-81.
14. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in COPD. Eur Respir J 2003; 22: 912-9.
15. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate/salmeterol combination delivered via the discus device in the treatment of COPD. Am J Respir Crit Care Med 2002; 166: 1084-91.
16. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of COPD. A randomized controlled trial. Lancet 2003; 361: 449-56.
17. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in COPD. N Engl J Med 2007; 356: 775-89.
18. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003794. DOI: 10.1002/14651858. CD003794.pub3.
19. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006826. DOI: 10.1002/14651858. CD006826.
20. Centanni S, Di Marco F. Budesonide and formoterol combination fort he treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2005; 6: 2525-34.
21. Halpin DMG. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int J Clin Pract 2005; 59: 1187-94.
22. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-50.
23. Worth H, Förster K, Eriksson G, et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010; 104: 1450-9.
24. Stockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin 2009; 25: 1235-45.
25. Watson L, Vonk JM, Löfdal CG, et al. Predictors of lung function and is decline in mild to moderate COPD in association with gender: results from the EUROSCOP study. Respir Med 2006; 100: 746-53.
26. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
27. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate COPD. Thorax 2006; 61: 849-53.
28. Wilkinson TM, Donaldson GC, Johnson SL, et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with COPD. Am J Respir Crit Care Med 2006; 173: 871-6.
29. Parr DG, Whte AJ, Bayley DL, et al. Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Med 2006; 7: 136.
30. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thoracic Soc 2005; 2: 26-33.
31. Crooks SW, Bayley DL, Hill SL, Stocley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of LTB4. Eur Respir J 2000; 15: 274-80.
32. Papi A, Bellattato CM, Braccioni F, et al. Infections and airway inflammation in COPD severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-21.
33. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-505.
34. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate COPD: a randomized controlled trial. Lancet 1999; 353: 1819-23.
35. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonid in persons with mild COPD who continue to smoke. N Engl J Med 1999; 340: 1948-53.
36. Burge PS, Calverley PMA, Jones PW, et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe COPD: the ISOLDE trial. BMJ 2000; 320: 1297-303.
37. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in COPD. N Engl J Med 2000; 343: 1902-9.
38. Sutherland ER, Allmers H, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in COPD: a meta analysis. Thorax 2003; 58: 937-41.
39. Alsaeedi A, Sin DD, McAliter FA. The effects of inhaled corticosteroids in COPD: a systematic review of randomized placebo- controlled trials. Am J Med 2002; 113: 59-65.
40. Soriano JB, Sin DD, Zhang X, et al. A pooled of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682-9.
41. Celli B, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.
42. Johnson M, Agusti AGN, Barnes NC. Reflection on TORCH: potential mechanisms fort he survival benefit of salmeterol/ fluticasone propionate in COPD patients. J COPD 2008; 5: 369-75.
43. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-71.
44. Halpin D. Mortality in COPD: inevitable or preventable? insights from the cardiovascular arena. J COPD 2008; 5: 187-200.
45. Jones PW, Agusti AGN. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-32.
46. Almagro P, Calbo E, Ochoa de Echagüen A, et al. Mortality after hospitalization for COPD. Chest 2002; 121: 1441-8.
47. Turkish Thoracic Society. Guideline for the diagnosis and management of chronic obstructive pulmonary disease. Turkish Toraks Journal 2010; 11: 1-64.
48. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-11.
49. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 2000; 160: 2653-8.
50. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-57.
51. Anthonisen NR, Skeans MA, Wise RA, et al; for the Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5 year mortality: a randomized controlled trial. Ann Intern Med 2005; 142: 233-9.
52. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-5.
53. Celli B, Decramer M, Kesten S, et al. UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;15;180:948-55.
54. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002; 166: 333-9.
55. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population based study and a systematic review of the literature. Chest 2005; 127: 1952-9.
56. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser permanente medical care program. Chest 2005; 128: 2068-75.
57. Wouters EFM, Celis MPM, Breyer MK, et al. Co-morbid manifestations in COPD. Respir Med 2007; 3: 135-51.
58. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799-809.
59. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-65.
60. Polatli M, Cakir A, Cildag O, et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008; 26: 97-102.
61. Kliber A, Lynd L, Sin DD. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res 2010; 11: 56-62.
62. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticosteroids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 227: 722-7.
63. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-9.
64. Löfdahl CG, Postma DS, Pride NB, et al. Possible protection by inhaled budesonide against ischemic cardiac events in mild COPD. Eur Respir J 2007; 29: 1115-9.
65. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
66. Jenkins CR, Jones PW, Calverley PMA, et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of COPD: analysis from the randomized, placebo-controlled TORCH study. Respir Res 2009; 10; 59-67.
67. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163: 1475-80.
68. Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 712-9.
69. Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med 2006; 12: 106-12.
70. Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy. Chest 2003; 123: 1460-6.
71. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance; change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28-33.
72. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-93.
73. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. J COPD 2010; 7: 375-82.
74. www.eclipse-copd.com.
75. Ernst P, Gonzalez AV, Suissa S, et al. Inhaled corticosteroids use in COPD and the risk of hospitalization for pnömonia. Am J Respir Crit Care Med 2007; 176: 162-6.
76. Soriano JB, Visick GT, Muellerova H, et al. Pattern of comorbidities in newly diagnosed COPD and asthma patients in primary care. Chest 2005; 128: 2099-107.
77. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/ salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 2008; 102: 1099-108.
78. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-9.
79. Drummond MB, Dasebrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable COPD: a systematic review and meta-analysis. JAMA 2008; 300: 2407-16.
80. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in COPD Arch Intern Med 2009; 169: 219-29.
81. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaled versus long-acting beta-agonist for COPD. Cochrane Database Syst Rev 2007; 4: CD006829.
82. Ernst P, Gonzalez AV, Suissa S, et al. Inhaled corticosteroids use in COPD and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-6.
83. Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH Study results. Thorax 2010; 65: 719-25.
84. Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable COPD. Cochrane Database Syst Rev 2007, CD002991.
85. Barnes PJ. Corticosteroids. In: Barnes PJ, Drazen JM, Rennard SI, Thomson NC (eds). Asthma and COPD. San Diego: Elsevier, 2009; 51: 639-53.
86. Roy A, Leblanc C, Paquette L, et al. Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Eur Respir J 1996; 9: 226-31.
87. Simmons FER, Persaud MP, Gillespie CA, et al. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993; 342: 736-8.
88. Ernst P, Baltzan M, Deschenes J, et al. Low-dose inhaled and nasal corticosteroids use and the risk of cataracts. Eur Respir J 2006; 27: 1168-74.